

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
(ROSPATENT) added to list of core patent offices covered
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS
National Meeting on March 13, 2005
NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 23 MAR 02 GBFULL: New full-text patent database on STN
NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:14:50 ON 13 MAR 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:15:18 ON 13 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4
DICTIONARY FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> axxyx/sqsp

L1 24 AXXYX/SQSP

=> x[valinqstyrk][avlistyprlhedw]xp[yf][rk]x/sqsp

L2 2 X[VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]X/SQSP

=> [valinqstyrk][avlistyprlhedw]xp[yf][rk]/sqsp

L3 276 [VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]/SQSP

=> fil embase, medline, caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 82.93 | 83.14 |

FILE 'EMBASE' ENTERED AT 17:16:10 ON 13 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 17:16:10 ON 13 MAR 2005

FILE 'CAPLUS' ENTERED AT 17:16:10 ON 13 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> l1 full

L4 24 L1

=> l2 full

L5 2 L2

=> l3 full

L6 94 L3

=> l6 sql<=8

MISSING OPERATOR L6 SQL<=8

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> FIL REGISTRY

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 14.23 | 97.37 |

FILE 'REGISTRY' ENTERED AT 17:17:47 ON 13 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4
DICTIONARY FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d his

(FILE 'HOME' ENTERED AT 17:14:50 ON 13 MAR 2005)

FILE 'REGISTRY' ENTERED AT 17:15:18 ON 13 MAR 2005

L1 24 AXXYX/SQSP
L2 2 X[VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]X/SQSP
L3 276 [VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]/SQSP

FILE 'EMBASE, MEDLINE, CAPLUS' ENTERED AT 17:16:10 ON 13 MAR 2005

L4 24 L1
L5 2 L2
L6 94 L3

FILE 'REGISTRY' ENTERED AT 17:17:47 ON 13 MAR 2005

=> FIL EMBASE, MEDLINE, CAPLUS
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.43 | 97.80 |

FULL ESTIMATED COST

FILE 'EMBASE' ENTERED AT 17:18:30 ON 13 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 17:18:30 ON 13 MAR 2005

FILE 'CAPLUS' ENTERED AT 17:18:30 ON 13 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> l6 and sql<=8

'8' NOT A VALID FIELD CODE
'8' NOT A VALID FIELD CODE
'8' NOT A VALID FIELD CODE
L7 0 L6 AND SQL<=8

=> FIL REGISTRY
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 2.15 | 99.95 |

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:18:51 ON 13 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4
DICTIONARY FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d his

(FILE 'HOME' ENTERED AT 17:14:50 ON 13 MAR 2005)

FILE 'REGISTRY' ENTERED AT 17:15:18 ON 13 MAR 2005

L1 24 AXXYX/SQSP
L2 2 X[VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]X/SQSP
L3 276 [VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]/SQSP

FILE 'EMBASE, MEDLINE, CAPLUS' ENTERED AT 17:16:10 ON 13 MAR 2005

L4 24 L1
L5 2 L2
L6 94 L3

FILE 'REGISTRY' ENTERED AT 17:17:47 ON 13 MAR 2005

FILE 'EMBASE, MEDLINE, CAPLUS' ENTERED AT 17:18:30 ON 13 MAR 2005

L7 0 L6 AND SQL<=8

FILE 'REGISTRY' ENTERED AT 17:18:51 ON 13 MAR 2005

=> 11 and sql<=8

310053 SQL<=8

L8 1 L1 AND SQL<=8

=> 12 and sql<=8

310053 SQL<=8

L9 0 L2 AND SQL<=8

=> 13 and sql<=8

310053 SQL<=8

L10 0 L3 AND SQL<=8

=> FIL EMBASE, MEDLINE, CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.66

114.61

FILE 'EMBASE' ENTERED AT 17:19:48 ON 13 MAR 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 17:19:48 ON 13 MAR 2005

FILE 'CAPLUS' ENTERED AT 17:19:48 ON 13 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> 18 full

L11 3 L8

```
=> dup rem l11
PROCESSING COMPLETED FOR L11
L12          3 DUP REM L11 (0 DUPLICATES REMOVED)
              ANSWERS '1-3' FROM FILE CAPLUS
```

```
=> d l12 ibib abs sqd 1-3
'SQD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):

ENTER DISPLAY FORMAT (BIB):bib

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:692096 CAPLUS
DN 139:308001
TI Synthesis and evaluation of methyl ether derivatives of the vancomycin,
teicoplanin, and ristocetin aglycon methyl esters
AU McComas, Casey C.; Crowley, Brendan M.; Hwang, Inkyu; Boger, Dale L.
CS Department of Chemistry and the Skaggs Institute for Chemical Biology, The
Scripps Research Institute, La Jolla, CA, 92037, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(17), 2933-2936
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:308001
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:287801 CAPLUS
DN 137:185805
TI Synthesis and evaluation of vancomycin and vancomycin aglycon analogues
that bear modifications in the residue 3 asparagine
AU McAtee, J. Jeffrey; Castle, Steven L.; Jin, Qing; Boger, Dale L.
CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The
Scripps Research Institute, La Jolla, CA, 92037, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(9), 1319-1322
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:185805
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:663038 CAPLUS
DN 132:64502
TI Total Synthesis of the Vancomycin Aglycon
AU Boger, Dale L.; Miyazaki, Susumu; Kim, Seong Heon; Wu, Jason H.; Castle,
Steven L.; Loiseleur, Olivier; Jin, Qing
CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The
Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of the American Chemical Society (1999), 121(43), 10004-10011
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 132:64502
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 all hit hitseq 1-3

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:692096 CAPLUS
DN 139:308001
ED Entered STN: 04 Sep 2003
TI Synthesis and evaluation of methyl ether derivatives of the vancomycin,
teicoplanin, and ristocetin aglycon methyl esters
AU McComas, Casey C.; Crowley, Brendan M.; Hwang, Inkyu; Boger, Dale L.
CS Department of Chemistry and the Skaggs Institute for Chemical Biology, The
Scripps Research Institute, La Jolla, CA, 92037, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(17), 2933-2936
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.

DT Journal
 LA English
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 26
 OS CASREACT 139:308001
 AB A series of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin A aglycon Me esters was synthesized and their antimicrobial activity was established. These derivs. exhibit increased activity against VanB resistant strains of bacteria equipotent with that observed with sensitive bacteria.
 ST vancomycin teicoplanin ristocetin deglycosylation prepn aglycon Me ester ether; glycopeptide aglycon Me ester ether prepn antibiotic resistance; natural product amine prepn methylation selective dehydration esterification etherification
 IT Methylation
 (O-methylation; preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT Glycosylation
 (deglycosylation; preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT Antibiotic resistance
 Antibiotics
 Esterification
 Etherification
 (preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT Aglycons
 Esters, preparation
 Ethers, preparation
 Natural products
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT Glycopeptides
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT Amines, preparation
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT Dehydration reaction
 (selective; preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT 1404-90-6, Vancomycin 11021-66-2, Ristocetin A 61036-62-2, Teicoplanin
 RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)
 IT 73201-25-9P, Ristomycin A aglycone 82198-76-3P, Vancomycin aglycon 89139-42-4P 214204-23-6P 611180-78-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and evaluation of Me ether derivs. of the vancomycin, teicoplanin, and ristocetin aglycon Me esters against antibiotic resistant organisms)

IT 253308-90-6P 611180-81-5P 611180-82-6P
 . RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and evaluation of Me ether derivs. of the vancomycin,
 teicoplanin, and ristocetin aglycon Me esters against antibiotic
 resistant organisms)

IT 104581-77-3P 104581-78-4P 135157-96-9P 309752-48-5P 309752-49-6P
 611180-74-6P 611180-75-7P 611180-76-8P 611180-77-9P 611180-79-1P
 611180-80-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and evaluation of Me ether derivs. of the vancomycin,
 teicoplanin, and ristocetin aglycon Me esters against antibiotic
 resistant organisms)

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Barry, A; J Clin Microbiol 1983, V23, P100
 (2) Boger, D; J Am Chem Soc 1998, V120, P8920 CAPLUS
 (3) Boger, D; J Am Chem Soc 1999, V121, P10004 CAPLUS
 (4) Boger, D; J Am Chem Soc 1999, V121, P3226 CAPLUS
 (5) Boger, D; J Am Chem Soc 2000, V122, P10047 CAPLUS
 (6) Boger, D; J Am Chem Soc 2000, V122, P7416 CAPLUS
 (7) Boger, D; J Am Chem Soc 2001, V123, P1862 CAPLUS
 (8) Brogden, R; Drugs 1994, V47, P823 CAPLUS
 (9) Cooper, M; Chem Biol 1999, V6, P891 CAPLUS
 (10) de Lalla, F; Drug Saf 1995, V13, P317 CAPLUS
 (11) Dong, S; J Am Chem Soc 2002, V124, P9064 CAPLUS
 (12) Ge, M; Science 1999, V284, P507 CAPLUS
 (13) Graninger, W; Drugs 1997, V54(Suppl 6), P21
 (14) Greenwood, D; Antimicrob Chemother 1988, V21(Suppl A), P1
 (15) Grundy, W; Antibiot Annu 1956-1957, P687 MEDLINE
 (16) Harris, C; J Am Chem Soc 1983, V105, P6915 CAPLUS
 (17) Herrin, T; US 4456593 CAPLUS
 (18) Hubbard, B; Angew Chem Int Ed 2003, V42, P730 CAPLUS
 (19) Kerns, R; J Am Chem Soc 2002, V122, P12608
 (20) Mackay, J; J Am Chem Soc 1994, V116, P4581 CAPLUS
 (21) Malabarba, A; Curr Med Chem 2001, V8, P1759 CAPLUS
 (22) Malabarba, A; Med Res Rev 1997, V17, P69 CAPLUS
 (23) McAtee, J; Bioorg Med Chem Lett 2002, V12, P1319 CAPLUS
 (24) McCormick, M; Antibiot Annu 1955-1956, P606 MEDLINE
 (25) Nicolaou, K; Angew Chem Int Ed 1999, V38, P2096
 (26) Pootoolal, J; Annu Rev Pharmacol Toxicol 2002, V42, P381 CAPLUS
 (27) Varaldo, P; Antimicrob Agents Chemother 1983, V23, P402 CAPLUS
 (28) Verbist, L; Antimicrob Agents Chemother 1984, V26, P881 CAPLUS
 (29) Walsh, C; Chem Biol 1996, V3, P21 CAPLUS
 (30) Walsh, C; Science 1993, V261, P308 CAPLUS
 (31) Wanner, J; Bioorg Med Chem Lett 2003, V13, P1169 CAPLUS
 (32) Westwell, M; Chem Commun 1996, P589 CAPLUS
 (33) Williams, D; Angew Chem Int Ed 1999, V38, P1172

IT 253308-90-6P 611180-81-5P 611180-82-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and evaluation of Me ether derivs. of the vancomycin,
 teicoplanin, and ristocetin aglycon Me esters against antibiotic
 resistant organisms)

IT 253308-90-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and evaluation of Me ether derivs. of the vancomycin,
 teicoplanin, and ristocetin aglycon Me esters against antibiotic
 resistant organisms)

RN 253308-90-6 CAPLUS
 CN Vancomycin, 3-(cyanomethyl)-3-de(2-amino-2-oxoethyl)-44-O-de[2-O-(3-amino-
 2,3,6-trideoxy-3-C-methyl- α -L-lyxo-hexopyranosyl)- β -D-
 glucopyranosyl]-28,30,32,44-tetra-O-methyl-, methyl ester (9CI) (CA INDEX
 NAME)

NTE modified (modifications unspecified)

/ Structure 8 in file .gra /

/ Structure 9 in file .gra /

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:287801 CAPLUS
DN 137:185805
ED Entered STN: 18 Apr 2002
TI Synthesis and evaluation of vancomycin and vancomycin aglycon analogues
that bear modifications in the residue 3 asparagine
AU McAtee, J. Jeffrey; Castle, Steven L.; Jin, Qing; Boger, Dale L.
CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The
Scripps Research Institute, La Jolla, CA, 92037, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(9), 1319-1322
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 26
OS CASREACT 137:185805
AB The synthesis and biol. evaluation of a set of residue 3 analogs of
vancomycin and its aglycon are described. These investigations follow
from the promising biol. activity of a protected and synthetically
modified vancomycin aglycon analog in which the asparagine side chain was
modified to possess a nitrile, rather than a carboxamide. Although this
modification typically was detrimental to antimicrobial activity,
hydrophobic vancomycin aglycon analogs that lack a lipid anchor as well as
the disaccharide are detailed that exhibit unusual potency against VanB,
but not VanA, resistant bacteria.
ST alkylation ester hydrolysis vancomycin analog aglycon prepn antibacterial;
Staphylococcus aureus Enterococcus faecium vancomycin antibacterial analog
aglycon prepn; antibiotic resistance Staphylococcus aureus Enterococcus
faecium vancomycin antibacterial analog
IT Peptides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant
or reagent)
(cyclic; preparation and evaluation of residue 3 modified vancomycin and
vancomycin aglycon analogs as antibacterial agents)
IT Hydrolysis
(ester; in the preparation of residue 3 modified vancomycin and vancomycin
aglycon analogs)
IT Alkylation
(in the preparation of residue 3 modified vancomycin and vancomycin aglycon
analog)
IT Antibacterial agents
(preparation and evaluation of residue 3 modified vancomycin and vancomycin
aglycon analogs as antibacterial agents)
IT Aglycons
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation and evaluation of residue 3 modified vancomycin and vancomycin
aglycon analogs as antibacterial agents)
IT Enterococcus faecium
Staphylococcus aureus
(preparation and evaluation of residue 3 modified vancomycin and vancomycin
aglycon analogs as antibacterial agents against)
IT Antibiotic resistance

(preparation and evaluation of residue 3 modified vancomycin and vancomycin aglycon analogs as antibacterial agents against resistant bacteria)

IT 448298-81-5P 448298-82-6P 448298-83-7P 448298-84-8P 448298-85-9P
448298-86-0P 448298-87-1P 448298-88-2P 448298-89-3P 448298-90-6P
448298-91-7P 448298-92-8P 448298-93-9P 448298-94-0P 448298-95-1P
448298-96-2P 448298-97-3P 448298-98-4P 448298-99-5P 448299-00-1P
449759-30-2P 449759-31-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(binding consts. of complex formation of)

IT 82198-76-3P, Vancomycin aglycone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and evaluation of as antibacterial agents)

IT 1404-90-6P, Vancomycin 214204-23-6P 250273-66-6P **253308-90-6P**
448298-72-4P 448298-73-5P 448298-74-6P 448298-75-7P 448298-76-8P
448298-77-9P 448298-78-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of as antibacterial agents)

IT 448298-79-1P 448298-80-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of in the preparation of residue 3 modified vancomycin and vancomycin aglycon analogs)

IT 221182-47-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of in the preparation of residue 3 modified vancomycin and vancomycin aglycon analogs)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Boger, D; J Am Chem Soc 1998, V120, P8920 CAPLUS
- (2) Boger, D; J Am Chem Soc 1999, V121, P10004 CAPLUS
- (3) Boger, D; J Am Chem Soc 1999, V121, P3226 CAPLUS
- (4) Copper, M; Chem Biol 1999, V6, P891
- (5) Harris, C; J Am Chem Soc 1983, V105, P6915 CAPLUS
- (6) Kerns, R; J Am Chem Soc 2000, V122, P12608 CAPLUS
- (7) Malabarba, A; Med Res Rev 1997, V17, P69 CAPLUS
- (8) McCormick, M; Antibiot Annu 1956, P606 CAPLUS
- (9) Nagarajan, R; Drugs and the Pharmaceutical Sciences Series 1994, P195 CAPLUS
- (10) Nagarajan, R; J Am Chem Soc 1988, V110, P7896 CAPLUS
- (11) Nicolaou, K; Angew Chem, Int Ed 1999, V38, P240 CAPLUS
- (12) Nicolaou, K; Chem Eur J 1999, V5, P2648 CAPLUS
- (13) Nieto, M; Biochem J 1971, V123, P773 CAPLUS
- (14) Perkins, H; Biochem J 1969, V111, P195 CAPLUS
- (15) Popieniek, P; Anal Biochem 1987, V165, P108 CAPLUS
- (16) Rao, A; Chem Rev 1995, V95, P2135 CAPLUS
- (17) Ray, R; Chem Biol 2001, V8, P1095
- (18) Scrimin, P; J Org Chem 1996, V61, P6268 CAPLUS
- (19) Walsh, C; Chem Biol 1996, V3, P21 CAPLUS
- (20) Weidemann, B; Antibiotics in Laboratory Medicine 1996, P900
- (21) Williams, D; Angew Chem, Int Ed 1999, V38, P1172
- (22) Williams, D; Chemtracts: Org Chem 1994, V7, P133 CAPLUS

IT 1404-90-6P, Vancomycin 214204-23-6P 250273-66-6P **253308-90-6P**
448298-72-4P 448298-73-5P 448298-74-6P 448298-75-7P 448298-76-8P
448298-77-9P 448298-78-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of as antibacterial agents)

IT **253308-90-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of as antibacterial agents)

RN 253308-90-6 CAPLUS

CN Vancomycin, 3-(cyanomethyl)-3-de(2-amino-2-oxoethyl)-44-O-de[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl- α -L-lyxo-hexopyranosyl)- β -D-glucopyranosyl]-28,30,32,44-tetra-O-methyl-, methyl ester (9CI) (CA INDEX

NAME)

NTE modified (modifications unspecified)

SEQ 1 LYAXXYX

/ Structure 10 in file .gra /

/ Structure 11 in file .gra /

L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:663038 CAPLUS
DN 132:64502
ED Entered STN: 19 Oct 1999
TI Total Synthesis of the Vancomycin Aglycon
AU Boger, Dale L.; Miyazaki, Susumu; Kim, Seong Heon; Wu, Jason H.; Castle, Steven L.; Loiseleur, Olivier; Jin, Qing
CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of the American Chemical Society (1999), 121(43), 10004-10011
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 33
OS CASREACT 132:64502
AB Full details of a diastereoselective total synthesis of the vancomycin aglycon are described. Two key aromatic nucleophilic substitution macrocyclizations with formation of the 16-membered diaryl ethers were enlisted for sequential CD and DE ring formations, an effective macrolactamization was developed for closure of the 12-membered biaryl AB ring system, and the defined order of CD, AB, and DE ring closures permitted selective thermal atropisomerism of the newly formed ring systems or their immediate precursors. This indirect control of the atropisomer stereochem. allowed all synthetic material to be funneled into the one of eight atropdiastereomers characterizing the natural product.
ST diastereoselective total synthesis prepn vancomycin aglycon
macrocyclization macrolactamization atropisomerism; arom nucleophilic substitution reaction diastereoselective total synthesis
IT Substitution reaction, nucleophilic
(aromatic; diastereoselective total synthesis of the vancomycin aglycon)
IT Macrocyclization
Stereochemistry
(diastereoselective total synthesis of the vancomycin aglycon)
IT Natural products
RL: SPN (Synthetic preparation); PREP (Preparation)
(diastereoselective total synthesis of the vancomycin aglycon)
IT Cyclization
(lactamization, macro; diastereoselective total synthesis of the vancomycin aglycon)
IT Atropisomers
(thermal; diastereoselective total synthesis of the vancomycin aglycon)
IT 139517-64-9P 207390-83-8P 214204-17-8P 214204-18-9P 214204-20-3P
214290-21-8P 223572-32-5P 223652-66-2P 223652-69-5P 223652-72-0P
223652-73-1P 223652-76-4P 223652-78-6P 253276-87-8P 253276-88-9P
253308-84-8P 253308-85-9P 253308-86-0P 253308-87-1P 253310-03-1P
253310-04-2P 253310-05-3P 253310-06-4P 253310-07-5P 253310-08-6P
253310-09-7P 253310-10-0P 253310-11-1P 253310-12-2P 253310-13-3P
253310-14-4P 253310-15-5P 253310-16-6P 253310-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of in the diastereoselective total synthesis of the vancomycin aglycon)

IT 82198-76-3P, Vancomycin aglycone 214204-23-6P 223572-45-0P
 223652-75-3P 253308-88-2P 253308-89-3P **253308-90-6P**
 253310-18-8P 253310-19-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of in the diastereoselective total synthesis of the vancomycin aglycon)

IT 2491-20-5, L-Alanine, methyl ester, hydrochloride 174146-44-2
 174290-57-4 199392-80-8 207390-81-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of in the diastereoselective total synthesis of the vancomycin aglycon)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Beugelmans, R; J Org Chem 1994, V59, P5535 CAPLUS
- (2) Boger, D; Bioorg Med Chem Lett 1995, V5, P1187 CAPLUS
- (3) Boger, D; Bioorg Med Chem Lett 1995, V5, P3091 CAPLUS
- (4) Boger, D; Bioorg Med Chem Lett 1996, V6, P1089 CAPLUS
- (5) Boger, D; Bioorg Med Chem Lett 1997, V7, P3199 CAPLUS
- (6) Boger, D; Bioorg Med Chem Lett 1998, V8, P721 CAPLUS
- (7) Boger, D; J Am Chem Soc 1998, V120, P8920 CAPLUS
- (8) Boger, D; J Am Chem Soc 1999, V121, P3226 CAPLUS
- (9) Boger, D; J Org Chem 1993, V58, P1425 CAPLUS
- (10) Boger, D; J Org Chem 1996, V61, P3561 CAPLUS
- (11) Boger, D; J Org Chem 1996, V61, P3938 CAPLUS
- (12) Boger, D; J Org Chem 1997, V62, P2054 CAPLUS
- (13) Boger, D; J Org Chem 1997, V62, P4721 CAPLUS
- (14) Boger, D; J Org Chem 1999, V64, P70 CAPLUS
- (15) Bois-Choussy, M; Tetrahedron Lett 1997, V38, P5795 CAPLUS
- (16) Brown, A; J Chem Soc Perkin Trans 1992, V1, P123
- (17) Evans, D; Angew Chem Int Ed 1998, V37, P2700 CAPLUS
- (18) Evans, D; Angew Chem Int Ed 1998, V37, P2704 CAPLUS
- (19) Evans, D; J Am Chem Soc 1997, V119, P3417 CAPLUS
- (20) Evans, D; J Am Chem Soc 1997, V119, P3419 CAPLUS
- (21) Evans, D; Tetrahedron Lett 1996, V37, P3251 CAPLUS
- (22) Harris, C; J Am Chem Soc 1983, V105, P6915 CAPLUS
- (23) Konishi, H; Tetrahedron Lett 1996, V37, P8791 CAPLUS
- (24) Malabarba, A; Med Res Rev 1997, V17, P69 CAPLUS
- (25) McCormick, M; Antibiot Annu 1955-1956, P606 MEDLINE
- (26) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2708 CAPLUS
- (27) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2714 CAPLUS
- (28) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2717 CAPLUS
- (29) Nicolaou, K; Angew Chem Int Ed 1999, V38, P240 CAPLUS
- (30) Paul, F; J Am Chem Soc 1995, V117, P5373
- (31) Pearson, A; J Org Chem 1997, V62, P4536 CAPLUS
- (32) Rao, A; Chem Rev 1995, V95, P2135 CAPLUS
- (33) Rao, A; Tetrahedron Lett 1994, V35, P8465 CAPLUS
- (34) Rao, A; Tetrahedron Lett 1996, V37, P3023 CAPLUS
- (35) Rao, A; Tetrahedron Lett 1997, V38, P7433 CAPLUS
- (36) Reddy, K; J Am Chem Soc 1998, V120, P1207 CAPLUS
- (37) Walsh, C; Chem Biol 1996, V3, P21 CAPLUS
- (38) Weidemann, B; Antibiotics in Laboratory Medicine 1996, P900
- (39) Williams, D; Angew Chem Int Ed 1999, V38, P1172
- (40) Williams, D; Chemtracts:Org Chem 1994, V7, P133 CAPLUS

IT 82198-76-3P, Vancomycin aglycone 214204-23-6P 223572-45-0P
 223652-75-3P 253308-88-2P 253308-89-3P **253308-90-6P**
 253310-18-8P 253310-19-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of in the diastereoselective total synthesis of the vancomycin aglycon)

IT **253308-90-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of in the diastereoselective total synthesis of the vancomycin aglycon)

RN 253308-90-6 CAPLUS
 CN Vancomycin, 3-(cyanomethyl)-3-de(2-amino-2-oxoethyl)-44-O-de[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl- α -L-lyxo-hexopyranosyl)- β -D-

glucopyranosyl]-28,30,32,44-tetra-O-methyl-, methyl ester (9CI) (CA INDEX
NAME)

NTE modified (modifications unspecified)

SEQ 1 LYAXXYX

/ Structure 12 in file .gra /

/ Structure 13 in file .gra /

=> DIS HIST

(FILE 'HOME' ENTERED AT 17:14:50 ON 13 MAR 2005)

FILE 'REGISTRY' ENTERED AT 17:15:18 ON 13 MAR 2005

L1 24 AXXYX/SQSP
L2 2 X[VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]X/SQSP
L3 276 [VALINQSTYRK][AVLISTYPR LHEDW]XP[YF][RK]/SQSP

FILE 'EMBASE, MEDLINE, CAPLUS' ENTERED AT 17:16:10 ON 13 MAR 2005

L4 24 L1
L5 2 L2
L6 94 L3

FILE 'REGISTRY' ENTERED AT 17:17:47 ON 13 MAR 2005

FILE 'EMBASE, MEDLINE, CAPLUS' ENTERED AT 17:18:30 ON 13 MAR 2005
L7 0 L6 AND SQL<=8

FILE 'REGISTRY' ENTERED AT 17:18:51 ON 13 MAR 2005

L8 1 L1 AND SQL<=8
L9 0 L2 AND SQL<=8
L10 0 L3 AND SQL<=8

FILE 'EMBASE, MEDLINE, CAPLUS' ENTERED AT 17:19:48 ON 13 MAR 2005

L11 3 L8
L12 3 DUP REM L11 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 36.66 | 151.27 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -2.19 | -2.19 |

STN INTERNATIONAL LOGOFF AT 17:23:30 ON 13 MAR 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptasjl1654

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | SEP 01 | New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! |
| NEWS | 4 | OCT 28 | KOREAPAT now available on STN |
| NEWS | 5 | NOV 30 | PHAR reloaded with additional data |
| NEWS | 6 | DEC 01 | LISA now available on STN |
| NEWS | 7 | DEC 09 | 12 databases to be removed from STN on December 31, 2004 |
| NEWS | 8 | DEC 15 | MEDLINE update schedule for December 2004 |
| NEWS | 9 | DEC 17 | ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected |
| NEWS | 10 | DEC 17 | COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected |
| NEWS | 11 | DEC 17 | SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected |
| NEWS | 12 | DEC 17 | CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected |
| NEWS | 13 | DEC 17 | THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB |
| NEWS | 14 | DEC 30 | EPFULL: New patent full text database to be available on STN |
| NEWS | 15 | DEC 30 | CAPLUS - PATENT COVERAGE EXPANDED |
| NEWS | 16 | JAN 03 | No connect-hour charges in EPFULL during January and February 2005 |
| NEWS | 17 | FEB 25 | CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered |
| NEWS | 18 | FEB 10 | STN Patent Forums to be held in March 2005 |
| NEWS | 19 | FEB 16 | STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005 |
| NEWS | 20 | FEB 28 | PATDPAFULL - New display fields provide for legal status data from INPADOC |
| NEWS | 21 | FEB 28 | BABS - Current-awareness alerts (SDIs) available |
| NEWS | 22 | FEB 28 | MEDLINE/LMEDLINE reloaded |
| NEWS | 23 | MAR 02 | GBFULL: New full-text patent database on STN |
| NEWS | 24 | MAR 03 | REGISTRY/ZREGISTRY - Sequence annotations enhanced |
| NEWS | 25 | MAR 03 | MEDLINE file segment of TOXCENTER reloaded |
| NEWS EXPRESS | | | JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005 |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:54:39 ON 13 MAR 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 17:55:47 ON 13 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4

DICTIONARY FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10798218-con-b-ex9-20050311.str



chain nodes :

1 2 3 4 5 6 16 17 18 19 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

ring nodes :

7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 41 42

chain bonds :

1-2 1-46 1-48 2-3 2-35 3-4 4-5 4-6 5-13 5-36 6-7 14-16 16-17 16-37 17-18 18-19
18-27 19-20 23-26 27-28 27-38 28-29 29-33 29-45 30-31 30-44 31-32 31-40 33-34
33-39 43-44 43-45 46-47 47-49 47-51 49-50 49-52 50-55 52-53 52-54 55-56 55-57

ring bonds :

7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41 15-42 20-21 20-25 21-22 22-23
23-24 24-25 41-42

exact/norm bonds :

1-46 2-3 2-35 3-4 5-13 5-36 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41
15-42 16-17 16-37 17-18 23-26 27-28 27-38 28-29 30-31 30-44 31-32 31-40 33-34
33-39 41-42 46-47 47-51 49-50 50-55 55-57

exact bonds :

1-2 1-48 4-5 4-6 6-7 14-16 18-19 18-27 19-20 29-33 29-45 43-44 43-45 47-49 49-52
52-53 52-54 55-56

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25


Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom 42:Atom 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10798218-con-b-ex10-20050311.str



chain nodes :

1 2 3 4 5 6 16 17 18 19 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

ring nodes :

7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 41 42

chain bonds :

1-2 1-46 1-48 2-3 2-35 3-4 4-5 4-6 5-13 5-36 6-7 14-16 16-17 16-37 17-18 18-19
18-27 19-20 23-26 27-28 27-38 28-29 29-33 29-45 30-31 30-44 31-32 31-40 33-34
33-39 43-44 43-45 46-47 47-49 47-51 48-56 49-50 49-52 50-53 52-57 53-54 53-55
57-58 57-59

ring bonds :

7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41 15-42 20-21 20-25 21-22 22-23
23-24 24-25 41-42

exact/norm bonds :

1-46 2-3 2-35 3-4 5-13 5-36 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41
15-42 16-17 16-37 17-18 23-26 27-28 27-38 28-29 30-31 30-44 31-32 31-40 33-34
33-39 41-42 46-47 47-51 49-50 50-53 53-55 57-58 57-59

exact bonds :

1-2 1-48 4-5 4-6 6-7 14-16 18-19 18-27 19-20 29-33 29-45 43-44 43-45 47-49 48-56
49-52 52-57 53-54

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25


Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom 42:Atom 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS

L2 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10798218-con-b-ex13-20050311.str



chain nodes :

1 2 3 4 5 6 16 17 18 19 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

ring nodes :

7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 41 42

chain bonds :

1-2 1-46 1-57 2-3 2-35 3-4 4-5 4-6 5-13 5-36 6-7 14-16 16-17 16-37 17-18 18-19
18-27 19-20 23-26 27-28 27-38 28-29 29-33 29-45 30-31 30-44 31-32 31-40 33-34
33-39 43-44 43-45 46-47 47-48 47-50 48-49 48-51 49-52 51-56 52-53 52-54 55-57

ring bonds :

7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41 15-42 20-21 20-25 21-22 22-23
23-24 24-25 41-42

exact/norm bonds :

1-46 2-3 2-35 3-4 5-13 5-36 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41
15-42 16-17 16-37 17-18 23-26 27-28 27-38 28-29 30-31 30-44 31-32 31-40 33-34
33-39 41-42 46-47 47-50 48-49 49-52 51-56 52-54 55-57

exact bonds :

1-2 1-57 4-5 4-6 6-7 14-16 18-19 18-27 19-20 29-33 29-45 43-44 43-45 47-48 48-51
52-53

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25


Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom 42:Atom 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS

L3 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10798218-con-b-ex14-20050311.str



```


chain nodes :
2 3 4 5 6 16 17 18 19 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 43
44 45 47 48 49 50 51 52 53 54 58 59 60 61
ring nodes :
1 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 41 42 46 55 56 57
chain bonds :
1-2 2-3 2-35 3-4 4-5 4-6 5-13 5-36 6-7 14-16 16-17 16-37 17-18 18-19 18-27 19-20
23-26 27-28 27-38 28-29 29-33 29-45 30-31 30-44 31-32 31-40 33-34 33-39 43-44
43-45 46-47 47-48 47-50 48-49 48-51 49-52 51-58 52-53 52-54 58-59 59-60 60-61
ring bonds :
1-46 1-55 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41 15-42 20-21 20-25 21-22
22-23 23-24 24-25 41-42 46-57 55-56 56-57
exact/norm bonds :
1-46 1-55 2-3 2-35 3-4 5-13 5-36 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41
15-42 16-17 16-37 17-18 23-26 27-28 27-38 28-29 30-31 30-44 31-32 31-40 33-34
33-39 41-42 46-47 46-57 47-50 48-49 49-52 52-54 55-56 56-57
exact bonds :
1-2 4-5 4-6 6-7 14-16 18-19 18-27 19-20 29-33 29-45 43-44 43-45 47-48 48-51 51-58
52-53 58-59 59-60 60-61
normalized bonds :
20-21 20-25 21-22 22-23 23-24 24-25

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom 42:Atom 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:Atom 56:Atom 57:Atom 58:CLASS 59:CLASS
60:CLASS 61:CLASS
  
```

L4 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10798218-con-b-ex16-20050311.str



```

chain nodes :
1 2 3 4 5 6 16 17 18 19 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
ring nodes :
7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 41 42
chain bonds :
1-2 1-46 1-56 2-3 2-35 3-4 4-5 4-6 5-13 5-36 6-7 14-16 16-17 16-37 17-18 18-19
18-27 19-20 23-26 27-28 27-38 28-29 29-33 29-45 30-31 30-44 31-32 31-40 33-34
33-39 43-44 43-45 46-47 47-48 47-50 48-49 48-51 49-52 51-55 52-53 52-54 56-57
56-58
ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41 15-42 20-21 20-25 21-22 22-23
23-24 24-25 41-42
exact/norm bonds :
1-46 2-3 2-35 3-4 5-13 5-36 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15 14-41
15-42 16-17 16-37 17-18 23-26 27-28 27-38 28-29 30-31 30-44 31-32 31-40 33-34
33-39 41-42 46-47 47-50 48-49 49-52 51-55 52-54
exact bonds :
1-2 1-56 4-5 4-6 6-7 14-16 18-19 18-27 19-20 29-33 29-45 43-44 43-45 47-48 48-51
52-53 56-57 56-58
normalized bonds :
20-21 20-25 21-22 22-23 23-24 24-25
  
```



```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom 42:Atom 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS
  
```

L5 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10798218-con-b-ex-20050311.str



```

chain nodes :
1 2 3 4 5 15 16 17 18 25 26 27 28 29 30 31 32 33 34 35 36 37 38 41 42
43
ring nodes :
6 7 8 9 10 11 12 13 14 19 20 21 22 23 24 39 40
chain bonds :
1-2 2-3 3-4 3-5 4-12 4-34 5-6 13-15 15-16 15-35 16-17 17-18 17-26 18-19 22-25
26-27 26-36 27-28 28-32 28-43 29-30 29-42 30-31 30-38 32-33 32-37 41-42 41-43
ring bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-14 13-39 14-40 19-20 19-24 20-21 21-22 22-23
23-24 39-40
exact/norm bonds :
1-2 2-3 4-12 4-34 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-14 13-39 14-40 15-16
15-35 16-17 22-25 26-27 26-36 27-28 29-30 29-42 30-31 30-38 32-33 32-37 39-40
exact bonds :
3-4 3-5 5-6 13-15 17-18 17-26 18-19 28-32 28-43 41-42 41-43
normalized bonds :
19-20 19-24 20-21 21-22 22-23 23-24

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:Atom 40:Atom
41:CLASS 42:CLASS 43:CLASS

```

L6 STRUCTURE UPLOADED

=> d 11-6

L6 HAS NO ANSWERS

'L1-6' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains data. (Default)

SIM ----- Structure Image.

SAT ----- Structure ATtributes and map table if it contains data.

SCT ----- Structure Connection Table and map table if it contains data.

SDA ----- All Structure Data (image, attributes, connection table and map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIM), NOS:o

'O' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains

• . data. (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
data.
SDA ----- All Structure DATA (image, attributes, connection table and
map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:end

=> d
L6 HAS NO ANSWERS
L6 STR
/ Structure 14 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> d 15
L5 HAS NO ANSWERS
L5 STR
/ Structure 15 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> d 14
L4 HAS NO ANSWERS
L4 STR
/ Structure 16 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> d 13
L3 HAS NO ANSWERS
L3 STR
/ Structure 17 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> d 12
L2 HAS NO ANSWERS
L2 STR
/ Structure 18 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> d 11
L1 HAS NO ANSWERS
L1 STR
/ Structure 19 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> 11
SAMPLE SEARCH INITIATED 18:00:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5609 TO ITERATE

17.8% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 107690 TO 116670
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L1

=> 12
SAMPLE SEARCH INITIATED 18:00:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4752 TO ITERATE

21.0% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 90907 TO 99173
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L2

=> 13
SAMPLE SEARCH INITIATED 18:00:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5389 TO ITERATE

18.6% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 103379 TO 112181
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L3

=> 14
SAMPLE SEARCH INITIATED 18:00:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3869 TO ITERATE

25.8% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 73650 TO 81110
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L4

=> 15
SAMPLE SEARCH INITIATED 18:00:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4461 TO ITERATE

22.4% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 85215 TO 93225
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L5

=> 16
SAMPLE SEARCH INITIATED 18:00:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5760 TO ITERATE

17.4% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 110650 TO 119750
PROJECTED ANSWERS: 0 TO 0

L12 0 SEA SSS SAM L6

=> DIS HIST

(FILE 'HOME' ENTERED AT 17:54:39 ON 13 MAR 2005)

FILE 'REGISTRY' ENTERED AT 17:55:47 ON 13 MAR 2005

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 STRUCTURE UPLOADED
L4 STRUCTURE UPLOADED
L5 STRUCTURE UPLOADED
L6 STRUCTURE UPLOADED
L7 0 L1
L8 0 L2
L9 0 L3
L10 0 L4
L11 0 L5
L12 0 L6

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| | | |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 3.87 | 4.29 |

STN INTERNATIONAL LOGOFF AT 18:01:10 ON 13 MAR 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptasjl1654

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?): 2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
(ROSPATENT) added to list of core patent offices covered
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS
National Meeting on March 13, 2005
NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 23 MAR 02 GBFULL: New full-text patent database on STN
NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:41:47 ON 13 MAR 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

| ENTRY | SESSION |
|-------|---------|
| 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 18:42:17 ON 13 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4
DICTIONARY FILE UPDATES: 11 MAR 2005 HIGHEST RN 845457-93-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> X[VALINQSTYRK][AVLISTYPR LHEDW]XX[YF]XX/SQSP
L1 57 X[VALINQSTYRK][AVLISTYPR LHEDW]XX[YF]XX/SQSP

=> 11 and sql<=8
310053 SQL<=8
L2 1 L1 AND SQL<=8

=> fil embase, medline, caplus
COST IN U.S. DOLLARS

| | SINCE FILE | TOTAL |
|---------------------|------------|---------|
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 33.39 | 33.60 |

FILE 'EMBASE' ENTERED AT 18:43:56 ON 13 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 18:43:56 ON 13 MAR 2005

FILE 'CAPLUS' ENTERED AT 18:43:56 ON 13 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> 12 full
L3 1 L2

=> d 13 all hit hitseq

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1124555 CAPLUS
DN 142:69212
ED Entered STN: 23 Dec 2004
TI Cell-permeable conjugates of peptides for inhibition of protein kinases,
pharmaceutical compositions, and therapeutic uses
IN Livnah, Nurit; Levitzki, Alexander; Senderovitz, Hanoch; Yechezkel, Tamar;
Salitra, Yosef; Litman, Pninit; Ohne, Osnat
PA Develogen Israel Ltd., Israel
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-12 (Pharmacology)

Section cross-reference(s): 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2004110337 | A2 | 20041223 | WO 2004-IL505 | 20040613 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | PRAI IL 2003-156429 | A | 20030612 | | |

CLASS

| | PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|----|--|-------|------------------------------------|
| | WO 2004110337 | ICM | A61K |
| AB | The invention provides inhibitors of protein kinases comprising a mol. having at least a first moiety competent for penetration of the mol. into cells, and a second moiety for having a protein kinase-inhibiting effect within the cells, the first moiety being joined to the second moiety through a linker or a spacer. The complex mols. of the invention are preferably peptide conjugates having improved cell permeability, serum stability, and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compns. comprising these protein kinase inhibitors, and methods of using such compns. for treatment of cancers and other diseases associated with protein kinase activity are also disclosed. | | |
| ST | peptide cell permeable conjugate protein kinase inhibitor; antitumor protein kinase inhibitor peptide conjugate; therapeutic protein kinase inhibitor peptide conjugate | | |
| IT | Wound healing (abnormal; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses) | | |
| IT | Antiarteriosclerotics (antiatherosclerotics; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses) | | |
| IT | Angiogenesis Angiogenesis inhibitors Anti-inflammatory agents Antidiabetic agents Antiobesity agents Antitumor agents Apoptosis Atherosclerosis Autoimmune disease Cardiovascular agents Cardiovascular system, disease Combination chemotherapy Cytotoxic agents Diabetes mellitus Drug delivery systems Fibrosis Immunomodulators Inflammation Kidney, neoplasm Leukemia Lung, neoplasm Mammary gland, neoplasm Melanoma Neoplasm Nervous system agents Obesity Ovary, neoplasm | | |

- Prostate gland, neoplasm
- Skin, neoplasm
- Stability
- Wound healing promoters
 - (cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Nervous system, disease
 - (central; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Intestine, neoplasm
 - (colon; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Peptidomimetics
 - (conjugates; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Peptides, biological studies
 - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (conjugates; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Animal tissue
 - (disorder of tissue not highly vascularized; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Biological transport
 - (drug; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Proteins
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (forkhead; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Shock (circulatory collapse)
 - (hemorrhagic; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Carcinoma
 - (hepatocellular; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Liver, neoplasm
 - (hepatoma; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Surgery
 - (insult to body tissue from; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Transplant and Transplantation
 - (proliferative response associated with; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Disease, animal
 - (proliferative; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Phosphorylation, biological
 - (protein; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Disease, animal
 - (repetitive motion disorder; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Artery, disease
 - (restenosis; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Amino acids, biological studies
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (spacer; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)
- IT Drug interactions
 - (synergistic; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 811789-64-7
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (.; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 56-65-5, Adenosine triphosphate, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ATP mimetic moiety; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 119-65-3D, Isoquinoline, derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ATP mimetic moiety; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 812810-11-0
 RL: PRP (Properties)
 (Unclaimed; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 142008-29-5, Protein kinase A 148640-14-6, Protein kinase B 372092-80-3, Protein kinase 391208-93-8, Glycogen synthase kinase 3
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 811788-92-8 811788-93-9 811788-94-0 811789-62-5 811789-63-6 811789-65-8 811789-66-9
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 811788-95-1P 811789-06-7P 811789-07-8P 811789-08-9P 811789-09-0P 811789-10-3P 811789-11-4P 812693-56-4P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 811788-90-6D, conjugates 811788-91-7D, conjugates 811788-92-8D, conjugates 811788-92-8D, conjugates with biotin, carboxyfluorescein or vitamin B6 811788-93-9D, conjugates 811788-94-0D, conjugates 811788-96-2 811788-97-3 811788-98-4 811788-99-5 811789-00-1 811789-01-2 811789-02-3 811789-03-4 811789-04-5 811789-05-6 811789-12-5 811789-13-6 811789-14-7 811789-15-8 811789-16-9 811789-17-0 811789-19-2 811789-20-5 811789-21-6 811789-22-7 811789-23-8D, conjugates with vitamin B6 811789-24-9 811789-25-0 811789-26-1 811789-27-2 811789-28-3D, derivs. 811789-29-4 811789-30-7 811789-31-8 811789-32-9 811789-33-0 811789-34-1 811789-35-2 811789-36-3 811789-37-4 811789-38-5 811789-39-6 811789-40-9 811789-41-0 811789-42-1 811789-43-2D, conjugates with spermine 811789-44-3 811789-45-4 811789-46-5 811789-47-6 811789-48-7 811789-49-8 811789-50-1 811789-51-2 811789-52-3 811789-53-4 811789-54-5 811789-55-6 811789-56-7 811789-57-8 811789-58-9 811789-59-0 811789-60-3 811789-61-4D, fitc labeled 812693-55-3 812693-57-5 812701-44-3
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 57-88-5D, Cholesterol, conjugates 1406-18-4D, Vitamin E, conjugates
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 865-21-4, Vinblastine 23214-92-8, Doxorubicin 33419-42-0, Etoposide 65271-80-9, Mitoxantrone 114977-28-5, Docetaxel
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 811789-18-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nod ch2,a nhj2cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 812810-07-4 812810-08-5 812810-09-6 812810-10-9 812810-12-1
 812810-13-2 812810-14-3 812810-15-4 812810-16-5 812810-17-6
 812810-18-7 812810-19-8 812810-20-1 812810-21-2 812810-22-3
 812810-23-4 812810-24-5 812810-25-6 812810-26-7 812810-27-8
 812810-28-9 812810-29-0 812810-30-3 812810-31-4 812810-32-5
 812810-33-6 812810-34-7 812810-35-8 812810-36-9 812810-37-0
 812810-38-1 812810-39-2 812810-40-5 812810-41-6 812810-42-7
 812810-43-8 812810-44-9 812810-45-0 **812810-46-1**
 812810-47-2 812810-48-3 812810-49-4 812810-50-7 812810-51-8
 812810-52-9
 RL: PRP (Properties)
 (unclaimed protein sequence; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 186186-89-0 188842-14-0
 RL: PRP (Properties)
 (unclaimed sequence; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT 812810-07-4 812810-08-5 812810-09-6 812810-10-9 812810-12-1
 812810-13-2 812810-14-3 812810-15-4 812810-16-5 812810-17-6
 812810-18-7 812810-19-8 812810-20-1 812810-21-2 812810-22-3
 812810-23-4 812810-24-5 812810-25-6 812810-26-7 812810-27-8
 812810-28-9 812810-29-0 812810-30-3 812810-31-4 812810-32-5
 812810-33-6 812810-34-7 812810-35-8 812810-36-9 812810-37-0
 812810-38-1 812810-39-2 812810-40-5 812810-41-6 812810-42-7
 812810-43-8 812810-44-9 812810-45-0 **812810-46-1**
 812810-47-2 812810-48-3 812810-49-4 812810-50-7 812810-51-8
 812810-52-9
 RL: PRP (Properties)
 (unclaimed protein sequence; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

IT **812810-46-1**
 RL: PRP (Properties)
 (unclaimed protein sequence; cell-permeable conjugates of peptides for inhibition of protein kinases, pharmaceutical compns., and therapeutic uses)

RN 812810-46-1 CAPLUS
 CN Peptide, (Xaa-Arg-Pro-Xaa-Xaa-Tyr-Xaa-Xaa) (9CI) (CA INDEX NAME)

SEQ 1 XRPXXYXX

=> DIS HIST
 Connection closed by remote host

---Logging off of STN---

END

Unable to generate the STN prompt.
 Exiting the script...